The PE Ratio as of July 2024 (TTM) for KalVista Pharmaceuticals, Inc. (KALV) is -4.30

According to KalVista Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -4.30. This represents a change of 26.73% compared to the average of -3.39 of the last 4 quarters.

KalVista Pharmaceuticals, Inc. (KALV) Historical PE Ratio (quarterly & annually)

How has KALV PE Ratio performed in the past?

The mean historical PE Ratio of KalVista Pharmaceuticals, Inc. over the last ten years is -5.66. The current -4.30 PE Ratio has changed 7.49% with respect to the historical average. Over the past ten years (40 quarters), KALV's PE Ratio was at its highest in in the September 2016 quarter at 0. The PE Ratio was at its lowest in in the April 2018 quarter at -39.52.

KalVista Pharmaceuticals, Inc. (KALV) PE Ratio by Quarter and Year

Discovering the peaks and valleys of KalVista Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

KalVista Pharmaceuticals, Inc. (KALV) Average PE Ratio

How has KALV PE Ratio performed in the past?

The current PE Ratio of KalVista Pharmaceuticals, Inc. (KALV) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

KalVista Pharmaceuticals, Inc. (KALV) PE Ratio vs. Peers

How is KALV’s PE Ratio compared to its peers?

KalVista Pharmaceuticals, Inc.’s PE Ratio is greater than Crinetics Pharmaceuticals, Inc. (-16.69), less than Theseus Pharmaceuticals, Inc. (-3.19), greater than Kura Oncology, Inc. (-10.53), greater than Viridian Therapeutics, Inc. (-4.67), less than Replimune Group, Inc. (-2.95), greater than Nuvectis Pharma, Inc. (-5.13), less than Lyra Therapeutics, Inc. (-0.29), less than Kronos Bio, Inc. (-0.68), less than Gossamer Bio, Inc. (-1.46), greater than Syndax Pharmaceuticals, Inc. (-8.67), less than Cogent Biosciences, Inc. (-4.25), greater than Cullinan Oncology, Inc. (-6.55), less than Mersana Therapeutics, Inc. (-1.89), greater than Immunocore Holdings plc (-24.67), greater than Mirum Pharmaceuticals, Inc. (-13.03), greater than Larimar Therapeutics, Inc. (-11.31), greater than Cytokinetics, Incorporated (-11.47), greater than DICE Therapeutics, Inc. (-23.17), greater than Edgewise Therapeutics, Inc. (-15.70), greater than Karuna Therapeutics, Inc. (-29.52), greater than Dyne Therapeutics, Inc. (-14.02),

Build a custom stock screener for KalVista Pharmaceuticals, Inc. (KALV) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like KalVista Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

KalVista Pharmaceuticals, Inc. (KALV) and other stocks custom spreadsheet templates

The easiest way to analyze a company like KalVista Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.